| Autor: |
Velázquez-Pérez L; Centro Para la Investigación y Rehabilitación de las Ataxias Hereditarias, Carretera Central Km 5 ½ Reparto Edecio Pérez, 80100 Holguín, Cuba. cirahsca2@cristal.hlg.sld.cu, Rodríguez-Chanfrau J, García-Rodríguez JC, Sánchez-Cruz G, Aguilera-Rodríguez R, Rodríguez-Labrada R, Rodríguez-Díaz JC, Canales-Ochoa N, Gotay DA, Almaguer Mederos LE, Laffita Mesa JM, Porto-Verdecia M, Triana CG, Pupo NR, Batista IH, López-Hernandez OD, Polanco ID, Novas AJ |
| Jazyk: |
angličtina |
| Zdroj: |
Neurochemical research [Neurochem Res] 2011 Oct; Vol. 36 (10), pp. 1793-800. Date of Electronic Publication: 2011 May 12. |
| DOI: |
10.1007/s11064-011-0496-0 |
| Abstrakt: |
Cuban patients with Spinocerebellar Ataxia type 2 (SCA2) have reduced concentrations of zinc in serum and cerebrospinal fluid (CSF). To assess the effect and safety of zinc supplementation, 36 Cuban SCA2 patients were randomly assigned to receive daily either 50 mg ZnSO(4) or placebo, together with neurorehabilitation therapy in a randomized, double-blind, placebo-controlled clinical trial during 6 months. Outcome measures included the changes of zinc levels in CSF and serum, ataxia score, oxidative stress and saccadic eye movements. At the end of the study, the Zinc-treated group showed: (i) a significant increase of the Zn levels in the CSF, (ii) mild decrease in the ataxia scale subscores for gait, posture, stance and dysdiadochocinesia (iii) reduction of lipid's oxidative damage, and (iv) reduction of saccadic latency when compared with the placebo group. The treatment was safe and well tolerated by all subjects. This study demonstrated the efficacy and safety of Zn supplementation, combined with neurorehabilitation for SCA2 patients and therefore it may encourage further studies on the clinical effect of zinc supplementation in SCA2 based in the conduction of future clinical trials with higher number of subjects. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink